Deleted Journal,
Год журнала:
2024,
Номер
unknown, С. 1 - 11
Опубликована: Окт. 8, 2024
Diabetes
mellitus
(DM)
is
a
very
prevalent
chronic
disease
worldwide,
including
in
Portugal,
and
it
accompanied
by
significant
morbidity
mortality.
People
with
DM
must
follow
the
National
Vaccination
Program.
Additionally,
Portuguese
Society
of
Endocrinology,
Diabetes,
Metabolism
(Sociedade
Portuguesa
de
Endocrinologia,
e
Metabolismo,
SPEDM)
has
drawn
up
position
statement
to
promote
speed
relevant
vaccination
coverage
people
thus
prevent
infections
reduce
impact
such
diseases
on
population
at
increased
risk.
This
includes
against
Streptococcus
pneumoniae,
influenza,
severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)/coronavirus
disease-2019
(COVID-19),
syncytial
virus
(RSV),
herpes
zoster
(HZ),
refers
adult
outside
context
pregnancy.
In
agreement
Directorate-General
Health
(Direcção-Geral
da
Saúde,
DGS),
2020,
SPEDM
recommended
immunization
13-valent
pneumococcal
polysaccharide
conjugate
vaccine
(PCV13)
23-valent
(PPV23)
adults
due
risk
invasive
disease.
Currently,
as
two
more
recent
vaccines
are
available,
preferentially
recommends,
this
population,
use
20-valent
(PCV20)
or,
an
alternative,
15-valent
(PCV15)
followed,
interval
12
months,
PPV23.
Annual
influenza
should
be
carried
out
accordance
DGS
norms
force;
among
groups
greatest
clinical
risk,
regardless
age.
SPEDM,
DGS,
also
recommends
SARS-CoV-2
DM,
following
proposed
schedules.
Considering
hospitalization
RSV
infection
for
aged
60
or
older,
especially
if
other
factors
coexist.
Finally,
given
greater
susceptibility
developing
HZ
its
complications,
50
years
well
18
older
immune
compromise,
factors,
personal
history
HZ.
changing
nature
epidemiological
context,
will
periodically
reviewed.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Апрель 18, 2024
Abstract
Monoclonal
antibodies
(mAbs)
targeting
the
SARS-CoV-2
receptor-binding
domain
(RBD)
showed
high
efficacy
in
prevention
and
treatment
of
COVID-19.
However,
rapid
evolution
has
rendered
all
clinically
authorized
mAbs
ineffective
continues
to
stymie
development
next-generation
mAbs.
Consequently,
ability
identify
broadly
neutralizing
(bnAbs)
that
neutralize
both
current
future
variants
is
critical
for
successful
antibody
therapeutic
development,
especially
newly
emerged
viruses
when
no
knowledge
about
immune
evasive
available.
Here,
we
have
developed
a
strategy
specifically
select
potent
bnAbs
with
activity
against
existing
prospective
based
on
accurate
viral
prediction
informed
by
deep
mutational
scanning
(DMS).
By
adopting
this
methodology,
increased
probability
identifying
XBB.1.5-effective
from
∼1%
40%
if
were
at
early
stage
pandemic,
as
revealed
retrospective
analysis
>1,000
wildtype
(WT)-elicited
From
collection,
identified
bnAb,
designated
BD55-1205,
exhibited
exceptional
historical,
contemporary,
predicted
variants.
Structural
analyses
extensive
polar
interactions
between
BD55-1205
XBB.1.5
motif
(RBM),
backbone
atoms,
explaining
its
unusually
broad
reactivity.
Importantly,
mRNA-based
delivery
IgG
human
FcRn-expressing
transgenic
mice
resulted
serum
titers
selected
XBB
BA.2.86
subvariants.
Together,
via
prediction,
coupled
speed
flexibility
mRNA
technology,
provides
generalized
framework
antibody-based
countermeasures
potentially
other
highly
variable
pathogens
pandemic
potential.
Expert Opinion on Biological Therapy,
Год журнала:
2024,
Номер
24(3), С. 191 - 201
Опубликована: Март 3, 2024
Introduction
Anti-spike
monoclonal
antibodies
(mAbs)
were
previously
authorized
for
the
prevention
and
treatment
of
COVID-19
in
immunocompromised
patients.
However,
they
are
no
longer
U.S.
due
to
their
lack
neutralizing
activity
against
current
circulating
SARS-CoV-2
Omicron
variants.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 14, 2025
SARS-CoV-2
monoclonal
antibodies
remain
the
only
option
for
prevention
or
treatment
of
COVID-19
those
with
immunodeficiencies
drug
interactions
antiviral
agents.
Here,
we
assess
neutralizing
activity
authorized
antibody
pemivibart
and
candidate
SA55
against
major
historical
currently
dominant
viral
variants,
including
JN.1
subvariants
KP.3.1.1
XEC.
Our
findings
show
that
demonstrates
broad
potency
while
exhibits
reduced
variants.
Then
employ
replication-competent
vesicular
stomatitis
virus
spike
(rVSVΔG-JN.1)
to
select
escape
variants
SA55.
Following
this,
conduct
a
systematic
comparison
profiles
these
two
antibodies,
revealing
is
remarkably
resilient
mutations
under
selection,
which
consistent
our
SPR
data
indicating
possesses
substantially
stronger
binding
affinity.
Moreover,
an
immunobridging
analysis
suggests
may
have
superior
clinical
efficacy
in
preventing
infection
current
variant
landscape.
Together,
this
work
highlights
promise
as
potential
therapeutic
COVID-19,
especially
immunocompromised
populations.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Апрель 1, 2024
ABSTRACT
The
Covid-19
pandemic
showcases
a
coevolutionary
race
between
the
human
immune
system
and
SARS-CoV-2,
mirroring
Red
Queen
hypothesis
of
evolutionary
biology.
generates
neutralizing
antibodies
targeting
SARS-CoV-2
spike
protein’s
receptor
binding
domain
(RBD),
crucial
for
host
cell
invasion,
while
virus
evolves
to
evade
antibody
recognition.
Here,
we
establish
synthetic
coevolution
combining
high-throughput
screening
RBD
variant
libraries
with
protein
mutagenesis,
surface
display,
deep
sequencing.
Additionally,
train
language
machine
learning
model
that
predicts
escape
variants.
Synthetic
reveals
antagonistic
compensatory
mutational
trajectories
variants,
enhancing
understanding
this
conflict.
